Pharmacokinetic definition

Pharmacokinetic Definition of Intestinal Absorption (fa), Presystemic Metabolism (Ec and Eh) and Absolute Bioavailability (F) of Drugs Administered Orally to Humans... 

Veng-Pedersen, P, Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II), Clin. Pharmacokinet., 17 424 40, 1989. Veng-Pedersen, R, Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I), Clin. Pharmacokinet., 17 345-366, 1989. Aarons, L., Mean residence time for drugs subject to reversible metabolism, J. Pharm. Pharmacol., 39 565-567, 1987. 

Lead structure According to Valler and Green s definition a lead structure is a representative of a compound series with sufficient potential (as measured by potency, selectivity, pharmacokinetics, physicochemical properties, absence of toxicity and novelty) to progress to a full drug development program [12]. 

To avoid confusion, several researchers have incorporated therapeutic intention into the definition of controlled release (4—7). Thus, controUed-release pharmaceuticals release dmgs in vivo according to a predictable, therapeutically rational, programmed rate to achieve the optimal dmg concentration in the minimal time (4). Specification by release rate complements specification by quantity jointly considered, they fix the duration of dmg release. Therefore, the dmg s duration of action can become a design property of a controlled release dosage form rather than an inherent pharmacokinetic property of the dmg molecule. 

Figure 2 Individual organ representations for a three-subcompartment (A), two-subcompartment (B), or typical membrane-linked and blood flow-limited (C) physiologically based pharmacokinetic model. See text for definition of symbols.

Figure 3 Possible blood circulation connections in a physiologically based pharmacokinetic model. (A) Venous return incorporated into lung mass balance equation (B) separate venous blood compartment. See text for definition of symbols.

The PBPK model development for a chemical is preceded by the definition of the problem, which in toxicology may often be related to the apparent complex nature of toxicity. Examples of such apparent complex toxic responses include nonlinearity in dose-response, sex and species differences in tissue response, differential response of tissues to chemical exposure, qualitatively and/or quantitatively difference responses for the same cumulative dose administered by different routes and scenarios, and so on. In these instances, PBPK modeling studies can be utilized to evaluate the pharmacokinetic basis of the apparent complex nature of toxicity induced by the chemical. One of the values of PBPK modeling, in fact, is that accurate description of target tissue dose often resolves behavior that appears complex at the administered dose level. 

Phase I studies evaluate the pharmacokinetics and safety of the drug in a small number (tens) of healthy volunteers. Phase I studies are sometimes conducted in a small patient population (Proof of Concept studies) with a specific objective such as the validation of the relevance of preclinical models in man. The purpose of these studies may be the rapid elimination of potential failures from the pipeline, definition of biological markers for efficacy or toxicity, or demonstration of early evidence of efficacy. These studies have a potential go/no-go decision criteria such as safety, tolerability, bioavailability/PK, pharmacodynamics, and efficacy. Dosage forms used in Phase I or Proof of Concept studies must be developed with the objectives of the clinical study in mind. 

There is a diversity of opinion regarding definitions and benefits of pharmacogenetics and pharmacogenomics.1 3 For example, pharmacogenetics is often considered to be the study of inter-individual variations in DNA sequence related to drug absorption and disposition (pharmacokinetics, PK) or drug action (pharmacodynamics, PD). Polymorphic variation in the genes that encode the functions of transporters,... 

Studies of pharmacokinetics could, in some instances, reveal that substantially different metabolic pathways are operating in the animal species used to collect toxicity information than operate in humans. It is often difficult to know how to use this type of information unless it is clear that the differences pertain to the metabolite(s) causing toxicity, and not the metabolites that have little or no role acquiring definitive data on this can often be problematic. 

For a number of years following the discovery and initial clinical use of vinblastine and vincristine, there was relatively little definitive information about the pharmacokinetics of these compounds. Pharmacokinetic studies were accomplished typically using radiolabeled drugs and procedures that were of limited value in distinguishing parent drugs from putative metabolites. 

Oral bioavailability is one of principal pharmacokinetic properties in drug discovery. It represents the percentage of an oral dose that is available to produce pharmacological actions, in other words, the fraction of the oral dose that reaches the system circulation in an active form. By the definition, when a drug is administered intravenously, its bioavailability is 100%. However, when a medication is administered via other routes, especially orally, its bioavailability decreases due to incomplete absorption and first-pass metabolism. 

---